A shortage of Concerta, a leading medication for attention-deficit/hyperactivity disorder (ADHD), has forced doctors to temporarily halt new prescriptions in Japan, leaving patients without necessary treatment. The shortage is attributed to a supply-demand imbalance, with the main ingredient of Concerta classified as a Schedule I psychotropic substance.
Shortage Causes
The shortage is mostly caused by a supply-demand imbalance, as the demand for Concerta has increased due to growing awareness of adult ADHD among the public and medical professionals. Additionally, the production of another ADHD medication was temporarily halted due to potentially carcinogenic impurities, leading many patients to switch to Concerta.
Japan faces shortage of ADHD medication Concerta. What does this mean for patients and families?
Impact on Patients
The shortage has affected thousands of ADHD patients in Japan, who are now facing difficulties in obtaining their medication. Some patients have reported experiencing basic errors and difficulties in daily life due to the lack of treatment.
The shortage of Concerta is a wake-up call for us to rethink our approach to treating ADHD. We need to focus on developing skills and providing support, rather than relying solely on medication.
Laura Lurns · Learning Success expert
Government Response
The Japanese government is working to increase the supply of Concerta, but the process is challenging due to the drug’s global production plans. The government is asking the manufacturer to increase Japan’s share of Concerta within the global supply.
Key takeaways
- Shortage Cause: Supply-demand imbalance
- Patient Impact: Thousands affected, difficulties in daily life
- Government Response: Working to increase supply
Looking Ahead
The situation is already affecting many individuals, and time is of the essence. The government and the pharmaceutical company must respond swiftly to resolve this issue. In the meantime, patients are advised to consult their healthcare providers for interim treatment plans.
The situation highlights the need for a more balanced approach to treating ADHD, with a focus on developing skills rather than relying on medication. The Learning Success All Access Program offers a free trial and a personalized Action Plan to help individuals with ADHD.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- Japan Times - ADHD drug shortage in Japan
